Switzerland – Swissmedic grants authorisation for the COVID-19 vaccine from Moderna

Second COVID-19 vaccine authorised in Switzerland

Following a thorough review of all the submitted data on safety, efficacy and quality, Swissmedic has today temporarily authorised the Moderna vaccine (COVID-19 mRNA Vaccine Moderna), which is based on an mRNA platform, for use in Switzerland. This means that a second COVID-19 vaccine has satisfied the strict requirements for safety, efficacy and quality and can be used with immediate effect in Switzerland. The authorisation studies have demonstrated a high efficacy rate of 94 percent 14 days after the second injection of the vaccine.

Supplementing its own internal review, Swissmedic granted temporary authorisation for the COVID-19 vaccine from Moderna after the independent Human Medicines Expert Committee (HMEC) had corroborated Swissmedic’s appraisal of the benefit/risk profile during its extraordinary meeting on 8 January 2021…